| Literature DB >> 15623708 |
J Rowin1, M N Meriggioli, E Tüzün, S Leurgans, P Christadoss.
Abstract
The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15623708 DOI： 10.1212/01.wnl.0000147242.92691.71
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910